Dihydropyridine calcium channel blockers tied to worse kidney outcomes in type 2 diabetes

Dihydropyridine calcium channel blockers may be linked to worse kidney outcomes for patients with type 2 diabetes, according to study data presented at the European Renal Association Congress in Glasgow, Scotland. Dihydropyridine calcium channel blockers (DCCBs) are a commonly prescribed antihypertensive medication for patients with diabetic kidney disease, according to Timna Agur, MD, senior

Raccontata dahealio.com